03.09.26 -- Life Sciences Hubs Creating More Opportunity For Startups And Investors

Laboratory testing services for biopharmaceutical development often are outsourced, but insourcing offers sponsors greater control and stability by combining provider expertise with sponsor infrastructure.

Discover how scalable lipid nanoparticle (LNP) technology is revolutionizing mRNA-based therapies and shaping the future of treatment innovation.

Explore how robotic gloveless isolators provide exceptional automation to eliminate human intervention, reduce contamination risk, and ensure compliance with the EU Annex 1 guideline.

Selecting the right GLP-1 peptide manufacturing route determines the specific impurity profile and regulatory strategy. Robust analytical methods are essential for ensuring efficacy and patient safety.

A new federal initiative is advancing bioprinted kidney tissue engineered from a patient’s own cells, combining cutting‑edge bioprinting, bioinks, and bioreactors to address the growing donor shortage.

Growing biologics demand is driving interest in perfusion culture as a complementary manufacturing strategy that enables continuous nutrient control, higher productivity, and performance when paired with fed-batch processes.